Actively Recruiting
Study of How Atirmociclib is Processed in Adults with Normal or Impaired Liver Function Using a Single Oral Dose
Led by Pfizer · Updated on 2026-08-21
28
Participants Needed
3
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the study medicine atirmociclib behaves in the body and its safety in adults with various levels of liver health. This phase 1 trial includes participants aged 18 years or older with a body mass index between 17.5 and 40 kgm2 and body weight over 50 kg. Participants may have normal liver function or stable mild, moderate, or severe liver disease. Participants will receive a single oral dose of atirmociclib. Those with normal liver function will stay in the clinic for about 7 days, while those with liver disease will stay for about 9 days. Blood samples will be collected at multiple time points to measure the amount of the medicine in the body over time, helping to understand how liver disease affects drug handling. During the study, participants will undergo medical evaluations including physical exams, laboratory tests, vital signs, and ECGs. Follow-up may occur by phone or clinic visits after leaving the clinic. The main outcome is the maximum observed plasma concentration of atirmociclib, measured at specific times after dosing. Safety is monitored through reports of adverse events and clinical laboratory abnormalities. The entire participation lasts about 9 weeks.
CONDITIONS
Brief Title
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here